Published in Blood Weekly, July 27th, 1998
To determine whether the ability to prevent bone marrow graft rejection could be separated from the ability to cause GVHD, Yoichiro Kusunoki, of the Fred Hutchinson Cancer Research Center, and colleagues generated a panel of four different CD8 cytotoxic T-lymphocyte clones specific for H2d alloantigens ("Prevention of Marrow Graft...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.